



Paul W. Abramowitz, Pharm.D., Sc.D. (Hon), FASHP
Chief Executive Officer

September 30, 2014

Ian T. Clark
Chief Executive Officer
Genentech, Inc.
One DNA Way
South San Francisco, CA 94080

Dear Mr. Clark:

I am writing to express ASHP's concerns about your recent announcement regarding the distribution of bevacizumab, trastuzumab, and rituximab through authorized specialty distributors. We respectfully ask that you place a moratorium on this change and meet with interested stakeholders to discuss the implications for patient care and the pharmaceutical supply chain.

ASHP represents pharmacists who serve as patient care providers in acute and ambulatory settings. The organization's more than 40,000 members include pharmacists, student pharmacists and pharmacy technicians. For over 70 years, ASHP has been on the forefront of efforts to improve medication use and enhance patient safety.

We have heard from many of our members, who believe that the current supply chain to their institutions, effectively addresses patient care needs while providing for financial and human resource efficiencies. This change by Genentech will potentially disrupt that.

We hope you will honor our request for a moratorium and will afford us and other stakeholders the opportunity to have a collegial discussion with you about how we can work together to best meet the needs of the patients we serve.

Sincerely,


Paul W. Abramowitz